Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Correction to: BMC Cancer (2017) 17:34

https://doi.org/10.1186/s12885-016-3038-y

Following publication of the original article [1], the author noticed the following errors in the article.

1) The following authors were mistakenly omitted from the published article:

• a. Dr. Shile Huang as lead corresponding author

• b. Dr. Chao Zhang as co-author

The correct authorship is as follows:

Wenxing Chen^1,2, Yanhong Pan¹, Siliang Wang¹, Yuping Liu¹, Guangying Chen³, Liang Zhou¹, Chao Zhang⁴, Wenting Ni¹, Aiyun Wang¹, Yin Lu^1,2* and Shile Huang⁴*.

* Correspondence: shuan1@lsuhsc.edu and luyingreen@126.com

2) Correction to Acknowledgement statement. The correct statement is as follows:

This work was supported in part by Natural Science Foundation of Jiangsu Province (BK2012854, W. Chen), National Natural Science Foundation of China (81673648, W. Chen;81173174, Y. Lu; 21162009, G. Chen), the National Institutes of Health NCI CA115414, S. Huang), American Cancer Society (RSG-08-135-01-CNE, S. Huang), Feist- Weiller Cancer Center, Louisiana State University Health Sciences Center, and a project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Qing Lan Project of Jiangsu and a preliminary foundation of NJUCM (13XYYZ4).

3) Correction to Authors’ contribution statement. The correct statement is as follows:

WXC, YL, and SH conceived the project and designed the research. WXC performed adenoviral and lentiviral assays, and YHP, YPL, WTN, and CZ conducted cell culture and western blot. SLW conducted the molecular docking. LZ prepared the figures and performed the statistical analysis. AYW, GYC, and YL participated in coordination. WXC wrote the manuscript. All authors read and approved the final manuscript.

4) Figure correction: The authors noticed an error in Fig. 8a. Please see the correct Fig. 8a and figure legend below.

Fig. 8

Activation of TSC2 involved in CPT inhibition of mTORC1 signaling. a Rh30 and DU145 cells were exposed to CPT (0–20 μmol/L) for 24 h, followed by western blotting with indicated antibodies

The authors apologize for any inconvenience caused.